Familial hypocalciuric hypercalcemia differential diagnosis: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Familial hypocalciuric hypercalcemia}} {{CMG}}; {{AE}} ==Overview== [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [c...")
 
No edit summary
 
(20 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Familial hypocalciuric hypercalcemia}}
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Familial_hypocalciuric_hypercalcemia]]
{{CMG}}; {{AE}}  
{{CMG}}; {{AE}}{{Ajay}}  


==Overview==
==Overview==
[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
[[Familial hypocalciuric hypercalcemia]] must be differentiated from [[primary hyperparathyroidism]] to avoid unnecessary [[parathyroidectomy]]. Calcium creatinine clearance ratio is used to differentiate [[FHH]] from [[primary hyperparathyroidism]], ratio < 0.01 suggestive of FHH  and > 0.01 suggestive of [[primary hyperparathyroidism]]. This [[genetic test]] of the CaSR gene is the gold standard. If negative, [[genetic testing]] for [[Mutation-selection balance|mutation]] of G alpha 11 and AP2S1 can [[diagnose]] FHH2 and FHH3, respectively.


OR
==Differentiating Familial Hypocalciuric Hypercalcemia From Other Diseases==


[Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].
[[Familial hypocalciuric hypercalcemia]] should be differentiated from other causes of [[hypercalcemia]]. Causes of [[hypercalcemia]] include:


==Differentiating X from other Diseases==
{| class="wikitable"
*[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|'''Parathyroid-related'''}}
*[Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|'''Non-parathyroid related'''}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|'''Medication-induced'''}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|'''Other'''}}
|-
|
* [[Primary hyperparathyroidism]]
* [[Secondary hyperparathyroidism]]
* [[Tertiary hyperparathyroidism]]
|
* [[Malignancy]]
* Humoral [[hypercalcemia]] of [[malignancy]]
* [[Osteolytic metasteses|Osteolytic]] [[tumors]]
* Production of [[calcitriol]] by tumors
* [[Ectopic]] parathyroid hormone production
|
* [[Thiazide diuretics]]
* [[Lithium]]
|
* [[Nutritional]]
* [[Milk-alkali syndrome]]
* [[Vitamin D -- adverse effects|Vitamin D toxicity]]
* [[Granulomatous|Granulomatous disease]]
* [[Sarcoidosis]]
* Surgical
* Immobilization
|}


*As [disease name] manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. [Subtype name 1] must be differentiated from other diseases that cause [clinical feature 1], such as [differential dx1] and [differential dx2]. In contrast, [subtype name 2] must be differentiated from other diseases that cause [clinical feature 2], such as [differential dx3] and [differential dx4].
{| class="wikitable"
 
! colspan="9" style="background: #4479BA; text-align: center;" |{{fontcolor|#FFF||Differential diagnosis of Familial Hypocalciuric Hypercalcemia on the basis of hypercalcemia}}
===Preferred Table===
|-
{|
! colspan="2" rowspan="2" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Disorder}}
|-style="background: #4479BA; color: #FFFFFF; text-align: center;"
! rowspan="2" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Mechanism of hypercalcemia}}
! rowspan="2" |Diseases
! rowspan="2" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Clinical features}}
! colspan="4" |Laboratory Findings
! colspan="4" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Laboratory findings}}
! colspan="4" |Physical Examination
! rowspan="2" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Imaging & diagnostic modalities}}
! colspan="4" |History and Symptoms
|-
! rowspan="2" |Other Findings
! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|PTH}}
|-style="background: #4479BA; color: #FFFFFF; text-align: center;"
! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Calcium}}
!Lab Test 1
! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Phosphate}}
!Lab Test 2
! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Other findings}}
!Lab Test 3
!Lab Test 4
!Physical Finding 1
!Physical Finding 2
!Physical Finding 3
!Physical Finding 4
!Finding 1
!Finding 2
!Finding 3
!Finding 4
|-
|-
|style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 1
| colspan="2" style="background: #F0FFFF; text-align: center;" |'''Familial hypocalciuric hypercalcemia'''
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC;" |
|style="background: #F5F5F5; padding: 5px;" |
* This is a genetic disorder caused by mutation in [[calcium-sensing receptor]] gene.
|style="background: #F5F5F5; padding: 5px;" |<nowiki>+</nowiki>
| style="background: #DCDCDC;" |
|style="background: #F5F5F5; padding: 5px;" |
* This is a benign condition and does not require treatment.
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" |Normal/↑
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" |Normal/↑
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" |
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC;" |
|style="background: #F5F5F5; padding: 5px;" |
* [[Calcium]]/[[creatinine]] clearance ratio
|style="background: #F5F5F5; padding: 5px;" |
|style="background: #F5F5F5; padding: 5px;" |
|style="background: #F5F5F5; padding: 5px;" |
|-
|-
|style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 2
| rowspan="3" style="background: #F0FFFF; text-align: center;" |'''[[Hyperparathyroidism]]'''
|style="background: #F5F5F5; padding: 5px;" |''''''
| style="background: #F0FFFF; text-align: center;" |[[Primary hyperparathyroidism]]
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC;" |Increase in [[secretion]] of [[parathyroid hormone]] (PTH) from a primary process in the [[parathyroid gland]]. [[Parathyroid hormone]] causes an increase in serum [[calcium]].
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC;" |
|style="background: #F5F5F5; padding: 5px;" |-
* Usually asymptomatic
|style="background: #F5F5F5; padding: 5px;" |
* [[Hypercalcemia]] detected on routine biochemical  panel
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" |
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" |
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" |↓/Normal
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" |Normal/↑ [[calcitriol]]
| style="background: #F5F5F5; padding: 5px;" |
| rowspan="3" style="background: #DCDCDC;" |Findings of bone resorption:
|style="background: #F5F5F5; padding: 5px;" |
* [[X-ray]]
|style="background: #F5F5F5; padding: 5px;" |
* [[DEXA scan|DEXA]]
|style="background: #F5F5F5; padding: 5px;" |
Preoperative localization of hyperfunctioning [[parathyroid gland]]:
* Non-Invasive
** [[Tc-99m sestamibi scintigraphy]]
** Neck ultrasound
** 4D-CT
** [[SPECT|SPET(P-SPECT)]]
** [[PET]]
** [[MRI]]
* Invasive:
** Super sensitive venous sampling
** Selective [[arteriography]]
** [[Angiography]]
Predicting post-operative success:
* Intraoperative [[parathyroid hormone]] monitoring
|-
|-
|style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 3
| style="background: #F0FFFF; text-align: center;" |[[Secondary hyperparathyroidism]]
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC;" |Increase in [[secretion]] of [[parathyroid hormone]] (PTH) from a secondary process. [[Parathyroid hormone]] causes an increase in serum calcium.
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC;" |
|style="background: #F5F5F5; padding: 5px;" |
* May present with history of:
|style="background: #F5F5F5; padding: 5px;" |
** [[Chronic renal failure]]
|style="background: #F5F5F5; padding: 5px;" |
** [[Vitamin D deficiency]]
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" |
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" |↓/Normal
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" |
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" | --
|style="background: #F5F5F5; padding: 5px;" |
|style="background: #F5F5F5; padding: 5px;" |
|style="background: #F5F5F5; padding: 5px;" |
|style="background: #F5F5F5; padding: 5px;" |
|-
|-
|style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 4
| style="background: #F0FFFF; text-align: center;" |Tertiary hyperparathyroidism
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC;" |Continuous elevation of [[parathyroid hormone]] (PTH) even after successful treatment of the secondary cause of elevated [[parathyroid hormone]]. [[Parathyroid hormone]] causes an increase in serum [[calcium]].
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC;" |
|style="background: #F5F5F5; padding: 5px;" |
* Usually present with a history of:
|style="background: #F5F5F5; padding: 5px;" |
** [[Kidney transplant]]
|style="background: #F5F5F5; padding: 5px;" |
* Usually [[hyperplasia]] of all four [[parathyroid glands]]
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" |
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" |
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" |
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" | --
|style="background: #F5F5F5; padding: 5px;" |
|style="background: #F5F5F5; padding: 5px;" |
|style="background: #F5F5F5; padding: 5px;" |
|style="background: #F5F5F5; padding: 5px;" |
|-
|-
|style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 5
| rowspan="4" style="background: #F0FFFF; text-align: center;" |'''Malignancy'''<ref name="pmid26713296">{{cite journal |vauthors=Mirrakhimov AE |title=Hypercalcemia of Malignancy: An Update on Pathogenesis and Management |journal=N Am J Med Sci |volume=7 |issue=11 |pages=483–93 |year=2015 |pmid=26713296 |pmc=4683803 |doi=10.4103/1947-2714.170600 |url=}}</ref>
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #F0FFFF; text-align: center;" |Humoral hypercalcemia of malignancy<ref name="pmid1346019">{{cite journal |vauthors=Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG |title=Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia |journal=Lancet |volume=339 |issue=8786 |pages=164–7 |year=1992 |pmid=1346019 |doi=10.1016/0140-6736(92)90220-W |url=}}</ref><ref name="pmid7962324">{{cite journal |vauthors=Ikeda K, Ohno H, Hane M, Yokoi H, Okada M, Honma T, Yamada A, Tatsumi Y, Tanaka T, Saitoh T |title=Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma |journal=J. Clin. Endocrinol. Metab. |volume=79 |issue=5 |pages=1322–7 |year=1994 |pmid=7962324 |doi=10.1210/jcem.79.5.7962324 |url=}}</ref><ref name="pmid12679445">{{cite journal |vauthors=Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF |title=Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue=4 |pages=1603–9 |year=2003 |pmid=12679445 |doi=10.1210/jc.2002-020773 |url=}}</ref>
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC;" |Tumor cells secrete [[Parathyroid hormone-related protein|parathyroidhormone-related protein]] ([[PTHrP]]) which acts similarly to [[parathyroid hormone]].
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC;" |
|style="background: #F5F5F5; padding: 5px;" |
* Most common cause of [[malignancy]] related [[hypercalcemia]].
|style="background: #F5F5F5; padding: 5px;" |
* Usually present in solid tumors
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" | --
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" |
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" |↓/Normal
|style="background: #F5F5F5; padding: 5px;" |
| style="background: #DCDCDC; text-align: center;" |↑ [[PTHrP]]
|style="background: #F5F5F5; padding: 5px;" |
|style="background: #F5F5F5; padding: 5px;" |
|style="background: #F5F5F5; padding: 5px;" |
|style="background: #F5F5F5; padding: 5px;" |
|}


===Use if the above table can not be made===
Normal/↑ [[calcitriol]]
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align=center
| style="background: #DCDCDC;" |
|valign=top|
* [[Chest X-ray]]
|+
* [[CT scan]]
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Differential Diagnosis}}
* [[MRI]]
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Similar Features}}
|-
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Differentiating Features}}
| style="background: #F0FFFF; text-align: center;" |Osteolytic tumors
| style="background: #DCDCDC;" |[[Multiple myeloma]] produces [[osteolysis]] of bones causing [[hypercalcemia]]. [[Osteolytic metasteses|Osteolytic metastasis]] can cause bone resorption causing [[hypercalcemia]].
| style="background: #DCDCDC;" |
* Most commonly present in [[multiple myeloma]] and [[breast cancer]].
| style="background: #DCDCDC; text-align: center;" |↓
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC;" |
* [[DXA]]
* [[X-ray]]
* [[Mammography]]
* [[Ultrasound]]
* [[ESR]]
* [[Serum protein electrophoresis]]
|-
| style="background: #F0FFFF; text-align: center;" |Production of [[calcitriol]]
| style="background: #DCDCDC;" |Some tumors have ectopic activity of 1-alpha-hydroxylase leading to increased production of [[calcitriol]]. [[Calcitriol]] is active form of [[vitamin D]] and causes [[hypercalcemia]].
| style="background: #DCDCDC;" |
* Most commonly present in [[lymphomas]] and in some [[Ovarian germ cell tumor|ovarian germ cell tumors]].
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" |↑ [[Calcitriol]]
| style="background: #DCDCDC;" |
* [[CT scan]]
* [[MRI]]
|-
| style="background: #F0FFFF; text-align: center;" |Ectopic [[parathyroid hormone]]<ref name="pmid16263810">{{cite journal |vauthors=VanHouten JN, Yu N, Rimm D, Dotto J, Arnold A, Wysolmerski JJ, Udelsman R |title=Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene |journal=J. Clin. Endocrinol. Metab. |volume=91 |issue=2 |pages=580–3 |year=2006 |pmid=16263810 |doi=10.1210/jc.2005-2095 |url=}}</ref>
| style="background: #DCDCDC;" |Some tumors leads to ectopic production of [[Parathyroid hormone|parathyroid hormone.]]
| style="background: #DCDCDC;" |
* In rare instances, [[small cell carcinoma]] of lung may produce [[hypercalcemia]] by this process.
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" |
| style="background: #DCDCDC; text-align: center;" |↓/Normal
| style="background: #DCDCDC; text-align: center;" |Normal/↑ Calcitriol
| style="background: #DCDCDC;" |
* [[Chest X-ray]]
* [[CT scan]]
* [[MRI]]
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"|Differential 1
| rowspan="2" style="background: #F0FFFF; text-align: center;" |'''Medication induced'''
| style="padding: 5px 5px; background: #F5F5F5;"|
| style="background: #F0FFFF; text-align: center;" |[[Lithium]]<ref name="pmid2918061">{{cite journal |vauthors=Mallette LE, Khouri K, Zengotita H, Hollis BW, Malini S |title=Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume |journal=J. Clin. Endocrinol. Metab. |volume=68 |issue=3 |pages=654–60 |year=1989 |pmid=2918061 |doi=10.1210/jcem-68-3-654 |url=}}</ref>
* On [physical exam; history; diagnostic test; imaging], [Differential 1] {has; demonstrates} [feature 1], [feature 2], [feature 3] also observed in [disease name].
| style="background: #DCDCDC;" |[[Lithium]] lowers urinary calcium and causes [[hypercalcemia]]. [[Lithium]] has been reported to cause an increase in [[Parathyroid hormone|parathyroid hormones]] and enlargement of [[parathyroid gland]] after weeks to months of therapy.
| style="padding: 5px 5px; background: #F5F5F5;"|
| style="background: #DCDCDC;" |
* On [physical exam; history; diagnostic test; imaging], [Differential 1] {has; demonstrates} [feature 1], [feature 2], [feature 3] that distinguish it from [disease name].
* History of mood disorder
| style="background: #DCDCDC; text-align: center;" |
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC;" |
* [[Lithium]] levels
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"|Differential 2
| style="background: #F0FFFF; text-align: center;" |[[Thiazide diuretics]]
| style="padding: 5px 5px; background: #F5F5F5;"|
| style="background: #DCDCDC;" |[[Thiazide diuretics]] lowers urinary calcium excretion and causes [[hypercalcemia]]
* On [physical exam; history; diagnostic test; imaging], [Differential 1] {has; demonstrates} [feature 1], [feature 2], [feature 3] also observed in [disease name].
| style="background: #DCDCDC;" |
| style="padding: 5px 5px; background: #F5F5F5;"|
* History of cardiac disorder
* On [physical exam; history; diagnostic test; imaging], [Differential 1] {has; demonstrates} [feature 1], [feature 2], [feature 3] that distinguish it from [disease name].
* Rarely causes [[hypercalcemia]]
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" |
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC;" | --
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"|Differential 3
| rowspan="2" style="background: #F0FFFF; text-align: center;" |'''Nutritional'''
| style="padding: 5px 5px; background: #F5F5F5;"|
| style="background: #F0FFFF; text-align: center;" |[[Milk-alkali syndrome]]
* On [physical exam; history; diagnostic test; imaging], [Differential 1] {has; demonstrates} [feature 1], [feature 2], [feature 3] also observed in [disease name].
| style="background: #DCDCDC;" |[[Hypercalcemia]] caused by high intake of [[calcium carbonate]]
| style="padding: 5px 5px; background: #F5F5F5;"|
| style="background: #DCDCDC;" |
* On [physical exam; history; diagnostic test; imaging], [Differential 1] {has; demonstrates} [feature 1], [feature 2], [feature 3] that distinguish it from [disease name].
* History of
** High milk intake
** Excess calcium intake for treating:
*** [[Osteoporosis]]
*** [[Dyspepsia]]
* May lead to [[metabolic alkalosis]] and renal insufficiency.
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" |
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC;" |
* [[Renal function tests|Renal function test]]
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"|Differential 4
| style="background: #F0FFFF; text-align: center;" |[[Vitamin D Intoxication|Vitamin D toxicity]]
| style="padding: 5px 5px; background: #F5F5F5;"|
| style="background: #DCDCDC;" |Excess [[vitamin D]] causes increased absorption of [[calcium]] from intestine causing [[hypercalcemia]].
* On [physical exam; history; diagnostic test; imaging], [Differential 1] {has; demonstrates} [feature 1], [feature 2], [feature 3] also observed in [disease name].
| style="background: #DCDCDC;" |
| style="padding: 5px 5px; background: #F5F5F5;"|
* History of:
* On [physical exam; history; diagnostic test; imaging], [Differential 1] {has; demonstrates} [feature 1], [feature 2], [feature 3] that distinguish it from [disease name].
** Excess intake [[vitamin D]]
** Excess milk fortified with [[vitamin D]]<ref name="pmid1313547">{{cite journal |vauthors=Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW |title=Hypervitaminosis D associated with drinking milk |journal=N. Engl. J. Med. |volume=326 |issue=18 |pages=1173–7 |year=1992 |pmid=1313547 |doi=10.1056/NEJM199204303261801 |url=}}</ref>
** Topical application of [[vitamin D]] analogue [[calcipotriol]]<ref name="pmid8120527">{{cite journal |vauthors=Hoeck HC, Laurberg G, Laurberg P |title=Hypercalcaemic crisis after excessive topical use of a vitamin D derivative |journal=J. Intern. Med. |volume=235 |issue=3 |pages=281–2 |year=1994 |pmid=8120527 |doi= |url=}}</ref>
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" |
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" |↑ [[Vitamin D]] ([[calcidiol]] and/or [[calcitriol]])
| style="background: #DCDCDC;" | --
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"|Differential 5
| style="background: #F0FFFF; text-align: center;" |'''[[Granulomatous|Granulomatous disease]]'''
| style="padding: 5px 5px; background: #F5F5F5;"|
| style="background: #F0FFFF; text-align: center;" |[[Sarcoidosis]]<ref name="pmid9215298">{{cite journal |vauthors=Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, Slatopolsky E |title=gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses |journal=J. Clin. Endocrinol. Metab. |volume=82 |issue=7 |pages=2222–32 |year=1997 |pmid=9215298 |doi=10.1210/jcem.82.7.4074 |url=}}</ref>
* On [physical exam; history; diagnostic test; imaging], [Differential 1] {has; demonstrates} [feature 1], [feature 2], [feature 3] also observed in [disease name].
| style="background: #DCDCDC;" |[[Hypercalcemia]] is caused by endogenous production of [[calcitriol]] by disease-activated [[macrophages]].
| style="padding: 5px 5px; background: #F5F5F5;"|
| style="background: #DCDCDC;" |
* On [physical exam; history; diagnostic test; imaging], [Differential 1] {has; demonstrates} [feature 1], [feature 2], [feature 3] that distinguish it from [disease name].
* History of:
** [[Cough]]
** [[Dyspnea]]
** [[Chest pain]]
** Tiredness or weakness
** [[Fever]]
** [[Weight loss]]
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" |
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" |
* ↑ [[Calcitriol]]
* ↑ [[ACE|ACE levels]]
| style="background: #DCDCDC;" |
* [[Chest X-ray]]
* [[Biopsy]]
|}
|}



Latest revision as of 20:40, 26 February 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ajay Gade MD[2]]

Overview

Familial hypocalciuric hypercalcemia must be differentiated from primary hyperparathyroidism to avoid unnecessary parathyroidectomy. Calcium creatinine clearance ratio is used to differentiate FHH from primary hyperparathyroidism, ratio < 0.01 suggestive of FHH and > 0.01 suggestive of primary hyperparathyroidism. This genetic test of the CaSR gene is the gold standard. If negative, genetic testing for mutation of G alpha 11 and AP2S1 can diagnose FHH2 and FHH3, respectively.

Differentiating Familial Hypocalciuric Hypercalcemia From Other Diseases

Familial hypocalciuric hypercalcemia should be differentiated from other causes of hypercalcemia. Causes of hypercalcemia include:

Parathyroid-related Non-parathyroid related Medication-induced Other
Differential diagnosis of Familial Hypocalciuric Hypercalcemia on the basis of hypercalcemia
Disorder Mechanism of hypercalcemia Clinical features Laboratory findings Imaging & diagnostic modalities
PTH Calcium Phosphate Other findings
Familial hypocalciuric hypercalcemia
  • This is a benign condition and does not require treatment.
Normal/↑ Normal/↑ --
Hyperparathyroidism Primary hyperparathyroidism Increase in secretion of parathyroid hormone (PTH) from a primary process in the parathyroid gland. Parathyroid hormone causes an increase in serum calcium.
  • Usually asymptomatic
  • Hypercalcemia detected on routine biochemical panel
↓/Normal Normal/↑ calcitriol Findings of bone resorption:

Preoperative localization of hyperfunctioning parathyroid gland:

Predicting post-operative success:

Secondary hyperparathyroidism Increase in secretion of parathyroid hormone (PTH) from a secondary process. Parathyroid hormone causes an increase in serum calcium. ↓/Normal --
Tertiary hyperparathyroidism Continuous elevation of parathyroid hormone (PTH) even after successful treatment of the secondary cause of elevated parathyroid hormone. Parathyroid hormone causes an increase in serum calcium. --
Malignancy[1] Humoral hypercalcemia of malignancy[2][3][4] Tumor cells secrete parathyroidhormone-related protein (PTHrP) which acts similarly to parathyroid hormone. -- ↓/Normal PTHrP

Normal/↑ calcitriol

Osteolytic tumors Multiple myeloma produces osteolysis of bones causing hypercalcemia. Osteolytic metastasis can cause bone resorption causing hypercalcemia. -- --
Production of calcitriol Some tumors have ectopic activity of 1-alpha-hydroxylase leading to increased production of calcitriol. Calcitriol is active form of vitamin D and causes hypercalcemia. -- -- Calcitriol
Ectopic parathyroid hormone[5] Some tumors leads to ectopic production of parathyroid hormone. ↓/Normal Normal/↑ Calcitriol
Medication induced Lithium[6] Lithium lowers urinary calcium and causes hypercalcemia. Lithium has been reported to cause an increase in parathyroid hormones and enlargement of parathyroid gland after weeks to months of therapy.
  • History of mood disorder
-- --
Thiazide diuretics Thiazide diuretics lowers urinary calcium excretion and causes hypercalcemia -- -- -- --
Nutritional Milk-alkali syndrome Hypercalcemia caused by high intake of calcium carbonate -- -- --
Vitamin D toxicity Excess vitamin D causes increased absorption of calcium from intestine causing hypercalcemia. -- -- Vitamin D (calcidiol and/or calcitriol) --
Granulomatous disease Sarcoidosis[9] Hypercalcemia is caused by endogenous production of calcitriol by disease-activated macrophages. -- --

References

  1. Mirrakhimov AE (2015). "Hypercalcemia of Malignancy: An Update on Pathogenesis and Management". N Am J Med Sci. 7 (11): 483–93. doi:10.4103/1947-2714.170600. PMC 4683803. PMID 26713296.
  2. Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG (1992). "Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia". Lancet. 339 (8786): 164–7. doi:10.1016/0140-6736(92)90220-W. PMID 1346019.
  3. Ikeda K, Ohno H, Hane M, Yokoi H, Okada M, Honma T, Yamada A, Tatsumi Y, Tanaka T, Saitoh T (1994). "Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma". J. Clin. Endocrinol. Metab. 79 (5): 1322–7. doi:10.1210/jcem.79.5.7962324. PMID 7962324.
  4. Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF (2003). "Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers". J. Clin. Endocrinol. Metab. 88 (4): 1603–9. doi:10.1210/jc.2002-020773. PMID 12679445.
  5. VanHouten JN, Yu N, Rimm D, Dotto J, Arnold A, Wysolmerski JJ, Udelsman R (2006). "Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene". J. Clin. Endocrinol. Metab. 91 (2): 580–3. doi:10.1210/jc.2005-2095. PMID 16263810.
  6. Mallette LE, Khouri K, Zengotita H, Hollis BW, Malini S (1989). "Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume". J. Clin. Endocrinol. Metab. 68 (3): 654–60. doi:10.1210/jcem-68-3-654. PMID 2918061.
  7. Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW (1992). "Hypervitaminosis D associated with drinking milk". N. Engl. J. Med. 326 (18): 1173–7. doi:10.1056/NEJM199204303261801. PMID 1313547.
  8. Hoeck HC, Laurberg G, Laurberg P (1994). "Hypercalcaemic crisis after excessive topical use of a vitamin D derivative". J. Intern. Med. 235 (3): 281–2. PMID 8120527.
  9. Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, Slatopolsky E (1997). "gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses". J. Clin. Endocrinol. Metab. 82 (7): 2222–32. doi:10.1210/jcem.82.7.4074. PMID 9215298.

Template:WH Template:WS